Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified Chemotherapy in High-Risk Soft Tissue Sarcoma
NCT03805022Phase 3Recruiting
- Sponsor
- Institut Bergonié
- Start
- Feb 2019
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of doxorubicin in soft tissue sarcoma (STS), sponsored by Institut Bergonié. Started Feb 2019; status: recruiting.
02
Drugs
doxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03805022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03805022.